{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T18:48:34Z","timestamp":1790621314072,"version":"4.1.0"},"reference-count":23,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2014,10,1]],"date-time":"2014-10-01T00:00:00Z","timestamp":1412121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,10,1]],"date-time":"2014-10-01T00:00:00Z","timestamp":1412121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["aacejournalendocrinepractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrine Practice"],"published-print":{"date-parts":[[2014,10]]},"DOI":"10.4158\/ep13477.or","type":"journal-article","created":{"date-parts":[[2014,8,12]],"date-time":"2014-08-12T21:59:07Z","timestamp":1407880747000},"page":"1070-1075","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Effects of Pramlintide in Patients with Type 2 Diabetes Mellitus: An Analysis Using Daily Insulin Dose Tertiles"],"prefix":"10.1016","volume":"20","author":[{"given":"Kathrin","family":"Herrmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Shan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven C.","family":"Brunell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steve","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.4158\/EP13477.OR_bb0005","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1111\/j.1742-1241.2008.01757.x","article-title":"Primary care physicians and insulin initiation: multiple barriers, lack of knowledge or both?","volume":"62","author":"Jabbour","year":"2008","journal-title":"Int J Clin Pract."},{"key":"10.4158\/EP13477.OR_bb0010","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1056\/NEJMoa0905479","article-title":"Three-year efficacy of complex insulin regimens in type 2 diabetes","volume":"361","author":"Holman","year":"2009","journal-title":"N Engl J Med."},{"key":"10.4158\/EP13477.OR_bb0015","series-title":"SYMLIN\u00ae (pramlintide acetate) injection for subcutaneous use (US Prescribing Information \u2013 revised August 2014)","author":"AstraZeneca Pharmaceuticals","year":"2014"},{"key":"10.4158\/EP13477.OR_bb0020","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1097\/00060793-199708000-00006","article-title":"Amylin\u2019s physiology and its role in diabetes","volume":"4","author":"Young","year":"1997","journal-title":"Curr Opin Endocrinol Diab."},{"key":"10.4158\/EP13477.OR_bb0025","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1517\/14656566.2011.581663","article-title":"Pramlintide and the treatment of diabetes: a review of the data since its introduction","volume":"12","author":"Younk","year":"2011","journal-title":"Expert Opin Pharmacother."},{"key":"10.4158\/EP13477.OR_bb0030","doi-asserted-by":"crossref","first-page":"203","DOI":"10.2147\/vhrm.2006.2.3.203","article-title":"Pramlintide in the management of insulin-using patients with type 2 and type 1 diabetes","volume":"2","author":"Pullman","year":"2006","journal-title":"Vasc Health Risk Manag."},{"key":"10.4158\/EP13477.OR_bb0035","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.2174\/1381612013397357","article-title":"Amylin replacement with pramlintide as an adjunct to insulin therapy in type 1 and type 2 diabetes mellitus: a physiological approach toward improved metabolic control","volume":"7","author":"Weyer","year":"2001","journal-title":"Curr Pharm Des."},{"key":"10.4158\/EP13477.OR_bb0040","doi-asserted-by":"crossref","first-page":"784","DOI":"10.2337\/diacare.26.3.784","article-title":"Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: a 1-year randomized controlled trial","volume":"26","author":"Hollander","year":"2003","journal-title":"Diabetes Care."},{"key":"10.4158\/EP13477.OR_bb0045","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1046\/j.1463-1326.2003.00295.x","article-title":"Addition of pramlintide to insulin therapy lowers HbA1c in conjunction with weight loss in patients with type 2 diabetes approaching glycaemic targets","volume":"5","author":"Hollander","year":"2003","journal-title":"Diabetes Obes Metab."},{"key":"10.4158\/EP13477.OR_bb0050","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1089\/15209150252924094","article-title":"Adjunctive therapy with the amylin analogue pramlintide leads to a combined improvement in glycemic and weight control in insulin-treated subjects with type 2 diabetes","volume":"4","author":"Ratner","year":"2002","journal-title":"Diabetes Technol Ther."},{"key":"10.4158\/EP13477.OR_bb0055","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1089\/dia.2006.0013","article-title":"Pramlintide as an adjunct to insulin in patients with type 2 diabetes in a clinical practice setting reduced A1C, postprandial glucose excursions, and weight","volume":"9","author":"Karl","year":"2007","journal-title":"Diabetes Technol Ther."},{"key":"10.4158\/EP13477.OR_bb0060","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S0140-6736(98)07019-6","article-title":"UK Prospective Diabetes Study (UKPDS) Group Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)","volume":"352","year":"1998","journal-title":"Lancet."},{"key":"10.4158\/EP13477.OR_bb0065","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1056\/NEJM199309303291401","article-title":"The Diabetes Control and Complications Trial Research Group The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus","volume":"329","year":"1993","journal-title":"N Engl J Med."},{"key":"10.4158\/EP13477.OR_bb0070","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/S0889-8529(05)70222-X","article-title":"Insulin therapy in type 2 diabetes","volume":"30","author":"Mudaliar","year":"2001","journal-title":"Endocrinol Metab Clin North Am."},{"key":"10.4158\/EP13477.OR_bb0075","first-page":"A151","article-title":"Pramlintide pharmacokinetics in type 1 and type 2 diabetes: effects of injection site, needle length and body size","volume":"53","author":"Weyer","year":"2004","journal-title":"Diabetes"},{"key":"10.4158\/EP13477.OR_bb0080","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.2337\/diacare.18.8.1113","article-title":"Veterans Affairs Cooperative Study on glycemic control and complications in type II diabetes (VA CSDM). Results of the feasibility trial. Veterans Affairs Cooperative Study in Type II Diabetes","volume":"18","author":"Abraira","year":"1995","journal-title":"Diabetes Care."},{"key":"10.4158\/EP13477.OR_bb0085","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1046\/j.1464-5491.2003.01072.x","article-title":"Hypoglycaemia in insulin-treated Type 2 diabetes: frequency, symptoms and impaired awareness","volume":"20","author":"Henderson","year":"2003","journal-title":"Diabet Med."},{"key":"10.4158\/EP13477.OR_bb0090","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s13300-013-0033-z","article-title":"Safety and effectiveness of biphasic insulin aspart 30 in different age-groups: A1chieve sub-analysis","volume":"4","author":"Khamseh","year":"2013","journal-title":"Diabetes Ther."},{"key":"10.4158\/EP13477.OR_bb0095","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.2337\/diacare.26.4.1176","article-title":"Frequency of severe hypoglycemia requiring emergency treatment in type 1 and type 2 diabetes: a population-based study of health service resource use","volume":"26","author":"Leese","year":"2003","journal-title":"Diabetes Care."},{"key":"10.4158\/EP13477.OR_bb0100","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1111\/j.1464-5491.1993.tb00051.x","article-title":"Frequency and morbidity of severe hypoglycaemia in insulin-treated diabetic patients","volume":"10","author":"MacLeod","year":"1993","journal-title":"Diabet Med."},{"key":"10.4158\/EP13477.OR_bb0105","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s13300-013-0026-y","article-title":"Safety and effectiveness of bolus insulin aspart in people with type 2 diabetes: A1chieve sub-analysis","volume":"4","author":"Randeree","year":"2013","journal-title":"Diabetes Ther."},{"key":"10.4158\/EP13477.OR_bb0110","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1001\/jama.1996.03540160044031","article-title":"Implantable insulin pump vs multiple-dose insulin for noninsulin-dependent diabetes mellitus: a randomized clinical trial. Department of Veterans Affairs Implantable Insulin Pump Study Group","volume":"276","author":"Saudek","year":"1996","journal-title":"JAMA."},{"key":"10.4158\/EP13477.OR_bb0115","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1056\/NEJMoa1006524","article-title":"Long-term effects of intensive glucose lowering on cardiovascular outcomes","volume":"364","author":"The ACCORD Study Group","year":"2011","journal-title":"N Engl J Med."}],"container-title":["Endocrine Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X20420968?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X20420968?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/aace.metapress.com\/index\/G1J4W8237T104P46.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:58:40Z","timestamp":1761515920000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1530891X20420968"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10]]},"references-count":23,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2014,10]]}},"alternative-id":["S1530891X20420968"],"URL":"https:\/\/doi.org\/10.4158\/ep13477.or","relation":{},"ISSN":["1530-891X"],"issn-type":[{"value":"1530-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2014,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effects of Pramlintide in Patients with Type 2 Diabetes Mellitus: An Analysis Using Daily Insulin Dose Tertiles","name":"articletitle","label":"Article Title"},{"value":"Endocrine Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.4158\/EP13477.OR","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}